And it’s just hard to say just exactly how to quantify that. I think by the time that we convene our next earnings call, I think we’ll have a much clearer picture of what that’s going to entail. But when you think about the condition that these millions and millions of patients are in, who have been diagnosed with sleep apnea, who know they suffer from it, but who are unable for a variety of reasons to use their CPAP machines, they really don’t have any other options. Short of some type of radical surgery or an implant like Inspire or something else, it’s very difficult for them to know what to do or how to treat their condition. And Vivos represents a huge alternative first line of defense type opportunity. And I think we’re creating relationships with payers, and we’re creating relationships with employers, and we’re creating relationships with these DME companies that are all going to be in a position to refer patients into Vivos providers across the country.
The fact that we have a network nationwide, the fact that we now have lower price point products and services, the fact that we have on differentiated technology is all very, very appealing to these groups. And I just think we’re kind of at that inflection point where it’s hard for us to predict, but we’re cautiously optimistic about what we’re seeing and the feedback we’re getting. And as Scott rightly pointed out, the bar has been set pretty high, and we’re shooting for it. But I would say that by this time, by the time we report on Q2, and we start talking about what’s going on with these new relationships, we’ll start to be able to grasp what this is going to mean. But I think it’s a definite inflection point for us, and we expect revenue and volume to increase dramatically here as we go into the second half of the year.
Lucas Ward : Okay, thanks, Kirk. One more question. You guys have mentioned that the AFD acquisition fills out an important product gap for you guys in terms of having more economical solutions for providers. Could you give us an update on the sales traction of the AFD devices?
Kirk Huntsman : Yeah. That’s going to be an easy one. Those are not yet reflected in any of our financials or returns. These products are a little bit technical. They’re a very different kind of technology than what we have in our — historically. So what we’ve had to do is create a whole new training program — but what we do know is that — because these products have been used by the Advanced Facialdontics doctors, they have been used for years and years. And there’s really several thousand patients that have benefited from the use of these products. So we have a very good grasp of what the products do, how efficacious they are. And now it’s time for us to train our doctors, retrain them on certain aspects of how to use products like the pod, and the sleep pod, and other devices.
But these products, they’re simpler, they require less chair time than our traditional products do. They don’t do all the things that our traditional products do, which is an important distinction. But from a doctor standpoint, they can fill and meet a need — they can fill a gap and meet a need at a very, very cost effective way with minimal chair time and very high levels of patient satisfaction. So as we mentioned — before, in the product offering was a little bit binary in that a patient either agreed to an $8,000 to $10,000 treatment plan or we really didn’t have anything to offer. It was really that the doctors, if they were going to take the case on, they were going to get paid well for it or they weren’t going to do it. Now the doctor can say, well, Mrs.
